Abstract
Background
Irritable bowel syndrome (IBS) is a chronic and episodic illness characterized by altered bowel habits and associated abdominal pain. At present, IBS is one of the most common functional gastrointestinal and motility disorders affecting countries around the world. Surveys have found that patients with IBS have a significantly lower health-related quality of life.
Objectives
The aim of this study was to translate and examine the validity of the Irritable Bowel Syndrome–Quality of Life questionnaire (IBS–QOL) in patients suffering from IBS in China.
Methods
A structured procedure was used for the translation and cultural adaptation of the original English IBS–QOL into Chinese. The questionnaire was administered to 73 clinical patients with IBS and␣70 healthy individuals. Psychometric testing for reliability, validity and responsiveness followed standardized procedures. Test–retest reliability (10–20 hours) was assessed using the clinical patients. Follow-up (4 weeks) was collected for 61 clinical patients. All enrolled patients also completed the Short Form-36 Health Survey (SF-36) at the baseline visit. Responsiveness to treatment (Venlafaxine and traditional Chinese herbal medicine) was assessed by one-way ANOVA methods.
Results
The average length of time required to complete the questionnaire was short (5.63 min for IBS patients and 5.54 min for healthy subjects by self-administration). Internal consistency (Cronbach’s alpha) values ranged from 0.722 to 0.914 for the Chinese IBS–QOL subscales and test–retest reliability coefficients were higher than 0.920 on all subscales. The convergent and discriminate validity results comparing the Chinese translation of the IBS–QOL overall score and the SF-36 subscales confirmed our predicted hypotheses. The Chinese IBS–QOL scores are more highly correlated with social functioning, vitality and general health (SF-36) and show weaker associations with physical functioning, role physical, mental health, and bodily pain (SF-36). The Chinese translation of the IBS–QOL was responsive to treatment.
Conclusion
In general, the Chinese translation of the IBS–QOL, after cultural adaptation and revision, possesses good reliability, validity and responsiveness. It is a reliable and valid instrument to assess the quality of life in Chinese patients suffering from IBS and is an appropriate measure to use in further clinical trials or for related research projects in China.
Article PDF
Avoid common mistakes on your manuscript.
References
Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002). AGA technical review on irritable bowel syndrome. Gastroenterology, 123, 2108–2131
Silk, D. B. A. (2003). Management of irritable bowel syndrome: start of a new era? European Journal of Gastroenterology & Hepatology, 15, 679–696
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine E. J., & Muller-Lissner, S. A. (1999). Functional bowel disorders and functional abdominal pain. Gut, 45, 43–47
Pan, G., Lu, S., Ke, M., et al. (2000). Epidemiology research of irritable bowel syndrome in Beijing: one whole group and random stratified sampling investigation. Chinese Journal of Epidemiology, 21, 26–29 (Chinese)
Xu, G., & Li S. (1999). Modern gastrointestinal disease. Beijing: People’s Military Medical Press, 860 pp (Chinese)
Bushnell, D., Patrick, D., Martin, M., Bracco, A., & Drossman, D. (2004). Further evaluation of the Irritable Bowel Syndrome–Quality of Life (IBS–QOL) Scale. Gut, 53, A66
Patrick, D. L., Drossman, D. A., Frederick, I. O., Dicesare, J., & Puder, K. L. (1998). Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure. Digestive Diseases and Sciences, 43(2), 400–411
Drossman, D. A., Toner, B. B., Whitehead, W. E., Diamant, N. E., Dalton, C. B., Duncan, S., Emmott, S., Proffitt, V. A., Kman, D., Frusciante, K., Le, T., Meyer, K., Bradshaw, B., Mikula, K., Morris, C. B., Blackman, C. J., Hu, Y., Jia, H., Li, J. Z., Koch, G. G., & Bangdiwala, S. I. (2003). Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology, 125, 19–31
Ricci, J. F., Walters, S., Ward, S., & Akehurst, R. (2003). Quality of life of IBS patients in the United Kingdom compared with a general population sample. Gastroenterology, 123, A518
Grüger, J., Schultes, H. J., Pirk, O., & van Assche D. (2001). The utility benefits of tegaserod in irritable bowel syndrome. Gut, 49, abstract no. 3001
Akehurst, R. L., Brazier, J. E., Mathers, N., O’Keefe, C., Kaltenthaler, E., Morgan, A., Platts, M., & Walters, S. J. (2002). Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics, 20, 455–462
Acquadro, C., Conway, K., Giroudet, C., & Mear I. (2004). Linguistic validation manual for patient-reported outcomes (PRO) instruments. Mapi Research Institute, Lyon
Guillemin, F., Bombardier, C., & Beaton, D. (1993). Cross-cultural adaptation of health related quality of life measure: Literature review and proposed guidelines. Journal of Clinical Epidemiology, 46, 1417–1432
Ware, J. E., & Sherbourne, C. D. (1992). The MOS 36-item short form survey (SF-36): 1. Conceptual framework and item selection. Medical Care, 30, 473–483
Guyatt, G. H., Feeny, D. H., & Patrick, D. L. (1993). Measuring health-related quality of life.Annals of Internal Medicine, 118, 622–629
SAC-MOT. (2002). Assessing health status and quality-of-life instruments: Attributes and review criteria. Quality of Life Research, 11, 193–205
Draft FDA PRO Guidance. (2006). Guidance for industry patient-reported outcome measures: Use in medical product development to support labeling claims. USA: U.S. Department of Health and Human Services Food and Drug Administration, pp 21–22
Cronbach, L. F. (1951). Coefficient alpha and the internal structure of tests. Psychometrika, 16, 297–334
Nunnally, J. C., & Bernstein, I. H. (1994). Psychometric theory. New York: McGraw-Hill, Inc
J. Fang (Ed.), (2000). Quality of life assessment and application. Beijing: Beijing Medical University Press. 72 pp (Chinese)
Streiner, D. L., & Norman, G. R. (1996). Health measurement scales: A practical guide to their development and use. 2nd edn. Oxford, UK: Oxford University Press
Patrick D. L., Drossman D. A., & Frederick I. O. (1997). A quality of life measure for persons with irritable bowel syndrome (IBS–QOL): User’s manual and scoring diskette. USA: University of Washington, 10 pp
Greenbaum, D. S., Mayle, J. E., Vanegeren, L. E., et al. (1987). Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Digestive Diseases and Sciences, 32, 257–266
Gorard, D. A., Libby, G. W., & Farthing, M. J. G. (1995). Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Digestive Diseases and Sciences, 40, 86–95
Kuiken, S. D., Burgers, P., Tytgat, G. N. J. et al. (2002). Fluoxetine (Prozac) for the treatment of irritable bowel syndrome: a randomized, controlled clinical trial. Gastroenterology, 122(4 Suppl), A-551
Krueger, K., McClain, J. et al. (2004). Nutritional supplements and alternative medicine. Gastroenterology, 20(2), 130–138
Langmead, L., Chitnis, M., et al. (2002). Use of complementary therapies by patients with IBD may indicate psychosocial distress. Inflammatory Bowel Diseases, 8(3), 174–179
Thompson, Don Lac. (2003). Complementary healthcare practices: East meets west: The use of traditional chinese medicine for gastrointestinal disorders. The Society of Gastroenterology Nurses & Associates, 26(6), 266
Zhou, F., Wu, W., & Huang, Z. (2002). Using Shun Ji He Ji to treat irritable bowel syndrome. Chinese International Journal of Medicine, 2(6), 503–505 (Chinese)
Zhou, F., Wu, W., & Huang, Z. (2002). The curative effect observation for using Shun Ji He Ji to treat irritable bowel syndrome. Journal of Guangzhou University of Traditional Chinese Medicine, 19(4), 269–271 (Chinese)
SPSS. Statistical Package for the Social Sciences Base 13.0 User’s Guide. USA, Chicago, ll: SPSS, Inc, 1999
Acknowledgements
The authors are grateful to Donald L. Patrick, Ph.D., USA, Douglas A. Drossman, MD, USA, Sin-yee Lee, HongKong, and the Mapi Research Trust for their efforts in supporting of this project. Thanks to Therese Anderson, Ph.D. (Melbourne, Australia) for editorial assistance.
The IBS–QOL was developed by Donald L. Patrick, Ph.D. at The University of Washington, Douglas A. Drossman, MD at The University of North Carolina, Novartis Pharmaceuticals Corporation, and Novartis Pharma AG. Authors hold joint copyright over the IBS–QOL and all its translations. Do not use without permission. For information on, or permission to use the IBS–QOL, please contact the Mapi Research Trust, 27 rue de la villette 69003 Lyon, France. Tel: +33-0-472136575, E-mail: trust@mapi.fr, website: www.mapi-trust.org. This article was presented orally at the 13th Annual Conference of the International Society for Quality of Life Research (ISOQOL) on October 12, 2006 in Lisbon, Portugal.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huang, Ww., Zhou, Fs., Bushnell, D.M. et al. Cultural adaptation and application of the IBS–QOL in China: a disease-specific quality-of-life questionnaire. Qual Life Res 16, 991–996 (2007). https://doi.org/10.1007/s11136-006-9141-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11136-006-9141-9